Literature DB >> 30020794

The Role of Glass Transition Temperatures in Coamorphous Drug-Amino Acid Formulations.

Eric Ofosu Kissi1, Georgia Kasten1, Korbinian Löbmann1, Thomas Rades1, Holger Grohganz1.   

Abstract

The improved physical stability associated with coamorphous drug-amino acid (AA) formulations may indicate a decrease in mobility of the amorphous drug molecules, compared to the neat amorphous form of the drug. Since the characteristic glass transition temperatures ( Tgα and Tgβ) represent molecular mobility in amorphous systems, we aimed to characterize Tgα and Tgβ and to determine their role in physical stability as well as their potential usefulness to determine the presence of an excess component (either drug or AA) in coamorphous systems. Indomethacin (IND)-tryptophan (TRP) and carvedilol (CAR)-TRP were used as model coamorphous systems. The analytical techniques used were X-ray powder diffractometry (XRPD) to determine the solid-state form, dynamic mechanical analysis (DMA) to probe Tgα and Tgβ, and differential scanning calorimetry (DSC) to probe thermal behavior of the coamorphous systems. Tgα analysis showed a gradual monotonous increase in Tgα values with increasing AA concentration, and this increase in the Tgα value is not the cause of the improved physical stability. The Tgβ analysis for the IND-TRP sample with 10% drug had a Tgβ of 226.8 K, and samples with 20-90% drug had similar Tgβ values around 212.5 K. For CAR-TRP, samples with 10-40% drug had similar Tgβ values around 230.5 K, and samples with 50-90% drug had similar Tgβ values around 223.3 K. The similar Tgβ values in coamorphous systems at different drug ratios indicate that they in fact are the Tgβ of the component that is in excess to an ideal drug-AA coamorphous mixture. DSC and XRPD analysis showed that for IND-TRP, IND is in excess if the drug concentration is 30% or above and will eventually recrystallize. For CAR-TRP, CAR is in excess and recrystallizes when the drug concentration is 50% or above. We have proposed a means of estimating, on the basis of Tgβ, which drug to AA ratios will lead to optimally physically stable coamorphous systems that can be considered for further development.

Entities:  

Keywords:  coamorphous; dynamic mechanical analysis; excess component; glass transition temperature; physical stability; β-relaxation

Mesh:

Substances:

Year:  2018        PMID: 30020794     DOI: 10.1021/acs.molpharmaceut.8b00650

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  5 in total

Review 1.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

2.  Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.

Authors:  Eric Ofosu Kissi; Keyoomars Khorami; Thomas Rades
Journal:  Pharmaceutics       Date:  2019-11-24       Impact factor: 6.321

3.  A Multivariate Approach for the Determination of the Optimal Mixing Ratio of the Non-Strong Interacting Co-Amorphous System Carvedilol-Tryptophan.

Authors:  Rong Di; Jingwen Liu; Holger Grohganz; Thomas Rades
Journal:  Molecules       Date:  2021-02-04       Impact factor: 4.411

4.  Mechanistic insights of the controlled release capacity of polar functional group in transdermal drug delivery system: the relationship of hydrogen bonding strength and controlled release capacity.

Authors:  Zheng Luo; Chao Liu; Peng Quan; Degong Yang; Hanqing Zhao; Xiaocao Wan; Liang Fang
Journal:  Acta Pharm Sin B       Date:  2019-11-29       Impact factor: 11.413

Review 5.  Co-Amorphous Drug Formulations in Numbers: Recent Advances in Co-Amorphous Drug Formulations with Focus on Co-Formability, Molar Ratio, Preparation Methods, Physical Stability, In Vitro and In Vivo Performance, and New Formulation Strategies.

Authors:  Jingwen Liu; Holger Grohganz; Korbinian Löbmann; Thomas Rades; Nele-Johanna Hempel
Journal:  Pharmaceutics       Date:  2021-03-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.